Orange Book product · Brand (NDA)
OLUMIANT
BARICITINIB
At a glance
Oct 08, 2019
Approved
Brand (NDA)
Application
AB
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 08, 2019
6 yr 10 mo ago
Today
Patent 8420629 expires
Listed method-of-use patent (U-247) expiration.
Mar 10, 2029
in 2 yr 9 mo
Patent 11806555 expires
Listed method-of-use patent (U-3500) expiration.
Nov 02, 2031
in 5 yr 5 mo
Patent 9737469 expires
Listed method-of-use patent (U-3500) expiration.
Nov 02, 2031
in 5 yr 5 mo
Patent 8158616 expires
Listed drug substance patent expiration.
May 31, 2032
in 6 yr
Patent 11045474 expires
Listed method-of-use patent (U-3372) expiration.
Nov 30, 2032
in 6 yr 7 mo
Patent 9089574 expires
Listed method-of-use patent (U-3372) expiration.
Nov 30, 2032
in 6 yr 7 mo
Pharmaceutical detail
Active ingredient
BARICITINIB
Strength
1MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 207924
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8420629 | Mar 10, 2029 | in 2 yr 9 mo | U-247 |
| 11806555 | Nov 02, 2031 | in 5 yr 5 mo | U-3500 |
| 9737469 | Nov 02, 2031 | in 5 yr 5 mo | U-3500 |
| 8158616 | May 31, 2032 | in 6 yr | SubstanceProduct |
| 11045474 | Nov 30, 2032 | in 6 yr 7 mo | U-3372 |
| 9089574 | Nov 30, 2032 | in 6 yr 7 mo | U-3372 |
